Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of REGN5713-5714-5715 in Healthy Adults and Birch Pollen Allergy
NCT03969849Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of REGN5713-5714-5715 in birch pollen allergy (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Treatment-Emergent Adverse Events up to 16 Weeks. Started Jun 2019; status: completed.
02
Drugs
REGN5713-5714-5715
03
Conditions
birch pollen allergy
Beyond the preview
Go deeper on NCT03969849.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03969849.